[go: up one dir, main page]

GB9910079D0 - Novel compounds - Google Patents

Novel compounds

Info

Publication number
GB9910079D0
GB9910079D0 GBGB9910079.4A GB9910079A GB9910079D0 GB 9910079 D0 GB9910079 D0 GB 9910079D0 GB 9910079 A GB9910079 A GB 9910079A GB 9910079 D0 GB9910079 D0 GB 9910079D0
Authority
GB
United Kingdom
Prior art keywords
novel compounds
novel
compounds
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
GBGB9910079.4A
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
SmithKline Beecham Ltd
Original Assignee
SmithKline Beecham Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by SmithKline Beecham Ltd filed Critical SmithKline Beecham Ltd
Priority to GBGB9910079.4A priority Critical patent/GB9910079D0/en
Publication of GB9910079D0 publication Critical patent/GB9910079D0/en
Priority to PCT/EP2000/003726 priority patent/WO2000066566A1/en
Priority to JP2000615597A priority patent/JP2002543189A/en
Priority to AU45567/00A priority patent/AU4556700A/en
Priority to EP00927053A priority patent/EP1173424A1/en
Ceased legal-status Critical Current

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D239/00Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46Two or more oxygen, sulphur or nitrogen atoms
    • C07D239/56One oxygen atom and one sulfur atom
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • A61P17/06Antipsoriatics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/02Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/18Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/12Antihypertensives
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D403/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/06Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D403/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Diabetes (AREA)
  • Neurology (AREA)
  • Rheumatology (AREA)
  • Psychiatry (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Endocrinology (AREA)
  • Urology & Nephrology (AREA)
  • Hospice & Palliative Care (AREA)
  • Hematology (AREA)
  • Emergency Medicine (AREA)
  • Vascular Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Obesity (AREA)
  • Dermatology (AREA)
  • Immunology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
GBGB9910079.4A 1999-05-01 1999-05-01 Novel compounds Ceased GB9910079D0 (en)

Priority Applications (5)

Application Number Priority Date Filing Date Title
GBGB9910079.4A GB9910079D0 (en) 1999-05-01 1999-05-01 Novel compounds
PCT/EP2000/003726 WO2000066566A1 (en) 1999-05-01 2000-04-25 Pyrimidine compounds
JP2000615597A JP2002543189A (en) 1999-05-01 2000-04-25 Pyrimidine compounds
AU45567/00A AU4556700A (en) 1999-05-01 2000-04-25 Pyrimidine compounds
EP00927053A EP1173424A1 (en) 1999-05-01 2000-04-25 Pyrimidine compounds

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB9910079.4A GB9910079D0 (en) 1999-05-01 1999-05-01 Novel compounds

Publications (1)

Publication Number Publication Date
GB9910079D0 true GB9910079D0 (en) 1999-06-30

Family

ID=10852633

Family Applications (1)

Application Number Title Priority Date Filing Date
GBGB9910079.4A Ceased GB9910079D0 (en) 1999-05-01 1999-05-01 Novel compounds

Country Status (5)

Country Link
EP (1) EP1173424A1 (en)
JP (1) JP2002543189A (en)
AU (1) AU4556700A (en)
GB (1) GB9910079D0 (en)
WO (1) WO2000066566A1 (en)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001060805A1 (en) 2000-02-16 2001-08-23 Smithkline Beecham P.L.C. Pyrimidine-4-one derivatives as ldl-pla2 inhibitors
GB0024808D0 (en) 2000-10-10 2000-11-22 Smithkline Beecham Plc Novel compounds
GB0119793D0 (en) * 2001-08-14 2001-10-03 Smithkline Beecham Plc Novel compounds
CA2487918A1 (en) 2002-05-31 2003-12-11 Janssen Pharmaceutica N.V. 3-descladinosyl-6-o-carbamoyl and 6-o-carbonoyl macrolide antibacterial agents
TW200643019A (en) * 2005-02-07 2006-12-16 Mitsubishi Pharma Corp Optically active tetrahydronaphthalene derivative
AU2006333522A1 (en) 2005-12-21 2007-07-12 Decode Genetics, Ehf. Biaryl nitrogen heterocycle inhibitors of LTA4H for treating inflammation
BRPI0721697A2 (en) 2007-05-11 2014-08-05 Univ Jefferson "METHODS FOR TREATING AND / OR PREVENTING NEURODEGENERATIVE DISEASE OR DISORDER IN AN INDIVIDUAL, TO TREAT AND / OR PREVENTING AN INDIVIDUAL WITH OR AT RISK OF VASCULAR DEMENTIA, TO TREAT AND / OR PREVENTING A BARRIERAL DISORDER OR DISORDER AN INDIVIDUAL, TO REDUCE BETA AMILOID ACCUMULATION IN THE BRAIN OF AN INDIVIDUAL, TO TREAT AND / OR PREVENT ALZHEIMER IN AN INDIVIDUAL AND TO PREVENT OR REDUCE THE RISK OF DEVELOPING ALZHHEIMER MISUSE, AND IN USE OF AND / OR LP-PLA2 PROTEIN ACTIVITY. "
JP5437996B2 (en) 2007-05-11 2014-03-12 ザ トラスティーズ オブ ザ ユニバーシティ オブ ペンシルバニア How to treat skin ulcers
US8889688B2 (en) 2010-01-05 2014-11-18 Actelion Pharmaceuticals Ltd. Piperazines as antimalarial agents
JP5165166B1 (en) 2010-01-05 2013-03-21 アクテリオン ファーマシューティカルズ リミテッド Novel piperazine as an antimalarial drug
US8470820B2 (en) 2010-01-22 2013-06-25 Hoffman-La Roche Inc. Nitrogen-containing heteroaryl derivatives
US8703768B2 (en) 2010-06-09 2014-04-22 Hoffmann-La Roche Inc. Nitrogen containing heteroaryl compounds
MX2013006342A (en) 2010-12-06 2013-08-26 Glaxo Group Ltd Pyrimidinone compounds for use in the treatment of diseases or conditions mediated by lp - pla2.
ES2847883T3 (en) 2010-12-17 2021-08-04 Glaxo Group Ltd Use of LP-PLA2 inhibitors in the treatment and prevention of eye diseases
AU2012288865B2 (en) 2011-07-27 2015-10-01 Glaxo Group Limited Bicyclic pyrimidone compounds
KR20140059203A (en) 2011-07-27 2014-05-15 글락소 그룹 리미티드 2,3-dihydroimidazo[1,2-c]pyrimidin-5(1h)-one compounds use as lp-pla2 inhibitors
JP2016505053A (en) 2013-01-25 2016-02-18 グラクソスミスクライン、インテレクチュアル、プロパティー、ディベロップメント、リミテッドGlaxosmithkline Intellectual Property Development Limited Bicyclic pyrimidone compounds as inhibitors of Lp-PLA2
CA2899124A1 (en) 2013-01-25 2014-07-31 Glaxosmithkline Intellectual Property Development Limited Compounds
AU2014209949B2 (en) 2013-01-25 2016-09-08 Glaxosmithkline Intellectual Property Development Limited 2,3-dihydroimidazol(1,2-c)pyrimidin-5(1h)-one based lipoprotein-associated phospholipase a2 (Lp-PLA2) inhibitors
WO2016012917A1 (en) 2014-07-22 2016-01-28 Glaxosmithkline Intellectual Property Development Limited 1,2,3,5-tetrahydroimidazo[1,2-c]pyrimidine derivatives useful in the treatment of diseases and disorders mediated by lp-pla2
WO2016012916A1 (en) 2014-07-22 2016-01-28 Glaxosmithkline Intellectual Property Development Limited 1,2,3,5-tetrahydroimidazo[1,2-c]pyrimidine derivatives useful in the treatment of diseases and disorders mediated by lp-pla2
JP2018505168A (en) * 2015-01-30 2018-02-22 ビーエーエスエフ ソシエタス・ヨーロピアBasf Se Herbicidal phenylpyrimidine
BR112022008786A2 (en) 2019-11-09 2022-07-26 Shanghai Simr Biotechnology Co Ltd COMPOUND, COMPOSITION, USE OF COMPOUND OR COMPOSITION, AND METHOD FOR TREATMENT OR PREVENTION OF A DIABETIC COMPLICATION, DISEASE RELATED TO NEUROINFLAMMATION OR ATHEROSCLEROSIS
CN115304620A (en) 2021-05-07 2022-11-08 上海赛默罗生物科技有限公司 Pyrimidone derivatives, preparation method, pharmaceutical composition and application thereof

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HU203736B (en) * 1989-04-06 1991-09-30 Gyogyszerkutato Intezet Process for producing new thiouracil-derivatives and pharmaceutical compositions containing them
DE69816471T2 (en) * 1997-11-06 2004-05-27 Smithkline Beecham P.L.C., Brentford PYRIMIDINONE COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM
JP2002523402A (en) * 1998-08-21 2002-07-30 スミスクライン・ビーチャム・パブリック・リミテッド・カンパニー Pyrimidinone for the treatment of atherosclerosis

Also Published As

Publication number Publication date
EP1173424A1 (en) 2002-01-23
JP2002543189A (en) 2002-12-17
WO2000066566A1 (en) 2000-11-09
AU4556700A (en) 2000-11-17

Similar Documents

Publication Publication Date Title
EP1140083A4 (en) Novel compounds
GB9910079D0 (en) Novel compounds
GB9902084D0 (en) Novel compounds
GB9902697D0 (en) Novel compounds
EG24063A (en) Novel compounds
GB9901256D0 (en) Novel compounds
GB9915044D0 (en) Novel compounds
GB9902070D0 (en) Novel compounds
GB9902937D0 (en) Novel compounds
GB9902880D0 (en) Novel compounds
GB9903278D0 (en) Novel compounds
GB9901462D0 (en) Novel compounds
GB9900959D0 (en) Novel compounds
GB9900952D0 (en) Novel compounds
GB9900162D0 (en) Novel compounds
GB9901209D0 (en) Novel compounds
GB9905058D0 (en) Novel compounds
GB9903536D0 (en) Novel compounds
GB9903535D0 (en) Novel compounds
GB9903417D0 (en) Novel compounds
GB9903416D0 (en) Novel compounds
GB9903414D0 (en) Novel compounds
GB9903402D0 (en) Novel compounds
GB9901946D0 (en) Novel compounds
GB9901602D0 (en) Novel compounds

Legal Events

Date Code Title Description
AT Applications terminated before publication under section 16(1)